• Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Leu97Pro (c.290T>C); ClinVar=VCV000962431; Zygosity=Unspecified (PubMed=23851445).
  
• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; c.662_672+40del; Zygosity=Unspecified (PubMed=23851445).
  

PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131
Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T., Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.
HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.
Cancer Immunol. Immunother. 58:1507-1515(2009)

PubMed=23348503; DOI=10.1126/science.1230062
Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.
TERT promoter mutations in familial and sporadic melanoma.
Science 339:959-961(2013)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)